Zdrowie i gospodarka · 10/05/2011

Biologics Price Competition and Innovation Act of 2009: Request for Comments on User Fee Program for Biosimilar and Interchangeable Biological Products

The Food and Drug Administration (FDA) is seeking public input on a proposed user fee program for biosimilar and interchangeable biological products, with a focus on fiscal years 2013 through 2017. The agency plans to use comments and meetings to develop recommendations for the program.